Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jul;60(1):103-104.
doi: 10.1111/apt.18057. Epub 2024 May 23.

Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease-Authors' reply

Tsz Hong Yiu  1 , Yanna Ko  2   3 , Aviv Pudipeddi  3 , Patrizia Natale  1   4   5 , Rupert W Leong  3
Affiliations
Comment

Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease-Authors' reply

Tsz Hong Yiu et al. Aliment Pharmacol Ther. 2024 Jul.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Alahmad M, Quraishi MN, Khan SW, Omar NM, Malik AT. Letter: early real‐world evidence from The United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease. Aliment Pharmacol Ther. 2024;60:101–102.
    1. Yiu TH, Ko Y, Pudipeddi A, Natale P, Leong RW. Meta‐analysis: persistence of advanced therapies in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2024;59(11):1312–1334. https://doi.org/10.1111/apt.18006
    1. Zinger A, Choi D, Choi N, Cohen RD, Rubin DT. Risankizumab effectiveness and safety in Crohn's disease: real‐world data from a large tertiary center. Clin Gastroenterol Hepatol. 2023;S1542‐3565(23):00998‐9.
    1. Ferrante M, Panaccione R, Colombel JF, Dubinsky M, Hisamatsu T, Lindsay JO, et al. DOP53 long‐ term efficacy and safety of Risankizumab in patients with moderate to severe Crohn's disease up to 3 years of treatment: results from the FORTIFY open‐label long‐term extension. J Crohns Colitis. 2024;18(Supplement_1):i168–i170.
    1. Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double‐blind, placebo‐controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet Lond Engl. 2022;399(10340):2031–2046.

LinkOut - more resources